ACHN News Alert Achillion Pharmaceuticals (ACHN) 10.23 11/05/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 5, 2014 at 5:53 AM

Achillion Pharmaceuticals (ACHN) 10.23 $ACHN

Nasdaq stocks posting largest percentage decreases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
BRDR: 7.01 (-3.83), ALIM: 5.02 (-0.18), ACHN: 10.23 (-1.89), FNHC: 29.21 (-1.20), ARCP: 8.15 (+0.30), CKEC: 28.36 (-0.08), JAXB: 10.50 (+1.65), PCLN: 1,097.70 (-100.82), TESO: 15.84 (-2.67)

Most active Nasdaq-traded stocks
AP - Tue Nov 04, 12:22PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
FB: 75.76 (+1.88), PLUG: 5.35 (+0.21), NYMX: 0.82 (-0.11), INTC: 34.54 (+0.23), FOX: 31.99 (-1.12), SAPE: 24.66 (+0.06), GERN: 2.68 (-0.12), ACHN: 10.23 (-1.89), FOXA: 33.33 (-1.02), ODP: 6.33 (+1.26), ARCP: 8.15 (+0.30), MSFT: 47.57 (+0.13), GRPN: 7.84 (+0.47), AAPL: 108.60 (-0.80)

Achillion Pharmaceuticals (ACHN) Stock Plummets on Lack of ACH-3422 Data in Quarterly Earnings
at The Street - Tue Nov 04, 10:31AM CST
Shares of Achillion Pharmaceuticals (ACHN) plunged in morning trading Tuesday after the company did not provide any data on its hepatitis C drug ACH-3422.
ACHN: 10.23 (-1.89)

Biotech Equities Coverage - Achillion Pharma, Sarepta Therapeutics, Alnylam Pharma, Incyte, and Cytori Therapeutics
PR Newswire - Tue Nov 04, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Achillion Pharmaceuticals Inc. (NASDAQ: ACHN), Sarepta Therapeutics Inc. (NASDAQ: SRPT), Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Incyte Corporation (NASDAQ: INCY), and Cytori Therapeutics Inc. (NASDAQ: CYTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Monday, November 03, 2014, the NASDAQ Composite ended at 4,638.91, up 0.18%, the Dow Jones Industrial Average edged 0.14% lower to finish the day at 17,366.24, and the S&P 500 closed at 2,017.81, down 0.01%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 779.04, up 0.02%, with the index also advancing 10.63% in the previous three months. Register for your complimentary reports on these five stocks at:
ALNY: 89.99 (-2.57), CYTX: 0.48 (-0.01), ACHN: 10.23 (-1.89), INCY: 67.76 (-0.21), SRPT: 16.38 (-0.02)

Achillion beats 3Q profit forecasts
Automated Insights - Tue Nov 04, 5:36AM CST
NEW HAVEN, Conn. (AP) _ Achillion Pharmaceuticals Inc. (ACHN) on Tuesday reported a loss of $15.7 million in its third quarter.
ACHN: 10.23 (-1.89)

Achillion Reports Third Quarter and Nine Month 2014 Financial Results
GlobeNewswire - Tue Nov 04, 5:30AM CST
- Hepatitis C development program remains on track to initiate all-oral ribavirin-free regimens with ACH-3422, ACH-3102 and sovaprevir for HCV in 2015 -
ACHN: 10.23 (-1.89)

Super Important Biotech and Drug Stock Events for November
at The Street - Mon Nov 03, 7:24AM CST
A cheat sheet of earnings, medical meetings, FDA approval decisions and clinical trial results for healthcare investors.
GILD: 109.72 (-0.26), CLVS: 58.95 (-1.28), ARWR: 6.41 (-0.11), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), RTRX: 10.28 (-0.10), RGLS: 20.25 (+0.20), EPZM: 25.43 (+0.28), AGIO: 82.44 (-0.63), RMTI: 10.63 (+1.88), ARNA: 4.31 (+0.09), KERX: 16.30 (-0.15)

Critical Alerts For NetSuite, CVS Caremark, Netflix, VeriFone Systems and Achillion Pharmaceuticals Released By InvestorsObserver
PR Newswire - Mon Oct 27, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for N, CVS, NFLX, PAY and ACHN.
NFLX: 382.78 (-5.63), ACHN: 10.23 (-1.89), CVS: 85.47 (-0.65), N: 108.92 (+1.66), PAY: 37.35 (+0.16)

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results
at The Street - Wed Oct 22, 7:39AM CDT
My question about Achillion and ACH-3422 question sparked a robust Twitter debate, which I've reproduced below with some additional comments and explanatory notes.
GILD: 109.72 (-0.26), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45), ABBV: 62.66 (-0.59)

Upcoming Earnings, Presentation of Clinical Data, Dividends, and Technical Updates - Research Reports on Achillion, KB Home, Hovnanian, QEP Resources and Fortune Brands
PR Newswire - Fri Oct 17, 8:30AM CDT
Today, Analysts Review released its research reports regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), KB Home (NYSE: KBH), Hovnanian Enterprises Inc. (NYSE: HOV), QEP Resources, Inc. (NYSE: QEP) and Fortune Brands Home & Security, Inc. (NYSE: FBHS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7277-100free.
QEP: 23.28 (-0.94), FBHS: 42.44 (-0.83), ACHN: 10.23 (-1.89), KBH: 15.69 (-0.30), HOV: 3.76 (-0.05)

November 28th Options Now Available For Achillion Pharmaceuticals (ACHN)
DividendChannel.com - Thu Oct 09, 10:04AM CDT
Investors in Achillion Pharmaceuticals Inc. saw new options become available today, for the November 28th expiration.
ACHN: 10.23 (-1.89)

Achillion to Present Updated Clinical HCV Data on ACH-3102 and Preclinical Profile of ACH-3422 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting
GlobeNewswire - Wed Oct 08, 9:23AM CDT
- Late breaker poster presentation will feature updated SVR results from the Phase 2 trial of ACH-3102, NS5A inhibitor, plus sofosbuvir for the eight-week treatment of genotype 1 HCV -
ACHN: 10.23 (-1.89)

Biotech Stock Mailbag: Seattle Genetics, Achillion, Catalyst Pharma
at The Street - Fri Oct 03, 8:41AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
JNJ: 108.62 (+1.16), SGEN: 36.57 (-0.68), CPRX: 2.97 (-0.06), ACHN: 10.23 (-1.89), SNSS: 1.68 (unch), BMY: 57.84 (+0.04)

Did Achillion Pharmaceuticals, Inc. Get Left Out in the M&A Cold?
Todd Campbell, The Motley Fool - Motley Fool - Wed Oct 01, 11:37AM CDT
Source: Achillion Pharmaceuticals. Achillion investors are probably shaking their heads wondering what's wrong with their company following Johnson & Johnson 's acquisition of the privately held Alios for $1.7 billion this week. On the...
JNJ: 108.62 (+1.16), GILD: 109.72 (-0.26), ACHN: 10.23 (-1.89)

J&J Buying Alios, Going Up Against Gilead
at Investor's Business Daily - Tue Sep 30, 11:02AM CDT
Medical giant Johnson & Johnson agreed to buy privately held biotech Alios BioPharma for $1.75 billion Tuesday, advancing its presence in viral diseases. Johnson & Johnson (JNJ) stock was up a fraction in morning trading on the stock market today. In...
JNJ: 108.62 (+1.16), VRTX: 114.10 (+1.12), GILD: 109.72 (-0.26), ACHN: 10.23 (-1.89), MRK: 59.37 (+0.45)

Why J&J Expands Antiviral Franchise but Doesn't Buy Achillion, Novavax
at The Street - Tue Sep 30, 8:49AM CDT
What are the motivations behind significant takeovers, like J&J's takeover of Alios Biopharma? And why have companies like Achillion and Novavax been passed over?
JNJ: 108.62 (+1.16), VRTX: 114.10 (+1.12), GILD: 109.72 (-0.26), NVAX: 5.55 (+0.03), ACHN: 10.23 (-1.89)

Critical Alerts For Achillion Pharmaceuticals, Dreamworks Animation, SunEdison, El Pollo Loco and Whole Foods Market Released By InvestorsObserver
PR Newswire - Tue Sep 30, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ACHN, DWA, SUNE, LOCO and WFM.
WFM: 39.80 (-0.15), SUNE: 19.65 (-0.36), ACHN: 10.23 (-1.89), LOCO: 36.19 (+0.49), DWA: 21.92 (-0.12)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

Oxford Bank Reports Strong Q3 Amid Challenges

Digging Into Oxford Bank's Q3 Numbers You ever wonder how a smaller banking outfit yet to become a household name manages to punch above its weight? Let's look at Oxford Bank Corporation's (OTCQX: OXBC) third-quarter antics, where dreams of better margins and loan growth dance, even as operational costs spike. Net Income Climbs Despite Rising Costs The headline here is...

Quaker Houghton Propels Forward with Q3 2026 Gains

Quaker Houghton's Strategy Yields Positive Q3 2026 Results Imagine getting through another quarter against global economic headwinds and coming out profitable. That’s exactly what Quaker Houghton (NYSE:KWR) pulled off in Q3 2026. Their net sales jumped to a solid $544.5 million, marking a 10% increase from the same quarter last year. Not bad for a company that had its...

Ashling's New Feat: Microsoft Recognition in AI

Microsoft's Stamp of Approval for Ashling Ah, recognition—it's not just for egos. When Ashling, an AI consultancy heavyweight, gets a nod from Microsoft, it's worth more than a footnote in the company newsletter. This isn't some participation trophy. Nope, it's a badge saying they know their Data & AI, and Digital & App Innovation inside out. On October 29, 2026,...

Wabi's $1.25B Valuation: A New Era for AI?

By Logan Wright Updated Oct 29, 2026 Category News Views 155

A Major Milestone for Wabi Well, here we go—Wabi, the brainchild of Eugenia Kuyda, is stirring the pot with a massive $55 million funding round, pulling its valuation up to a hefty $1.25 billion. If you're raising eyebrows at that price tag, you’re not alone. It's a big number riding on an even bigger idea: that AI isn't just for solitary chats anymore, but for...

OPC Energy Refinances $825M for U.S. Power Plants

Strategic Financial Move for OPC Energy Here's the scoop from the powerhouse behind some major U.S. electricity moves: OPC Energy and its subsidiary CPV nailed down a hefty $825 million financing package for the Shore and Maryland power plants. This isn’t just any old financial shuffle. Nope, they've hammered out an all-in-one refinancing deal that's setting the stage...

Tata's $450M Bet on India's AI Infrastructure

The Big Bet on AI Infrastructure Here comes Tata Communications, tossing nearly USD 450 million into the pot, betting on a vision that could change India's digital backbone. This isn't just some drop in the bucket; they're talking about laying down 10,000 kilometers of fiber for India's AI super highway. It's a gutsy move, and frankly, it's about time someone shook things...

YSS Faces Legal Heat Over Misleading Investor Claims

YSS Investors Navigate Legal Waters as Class Action Looms Taking a slug of coffee this morning and diving right into it—York Space Systems has found itself in hot water. They went public earlier this year with what was supposed to be a shining opportunity under the NYSE:YSS ticker, but it turns out that not everything in their IPO shined—and now SBS Law is stepping up...

CATL's Bold Move: New Energy Storage Game Changer

Fresh Energy on the Aussie Horizon Ever see a heavyweight step into the ring and know it's about to shake things up? That's CATL breaking into Australia with their new TENER+ system. This ain't just talk—these guys are delivering ultra-high capacity energy storage aimed right at the heart of the Australian energy sector, just in time for All Energy 2026. A Big Play in...

kidSTREAM Museum Welcomes Carina Reeves as New CEO

Carina Reeves Takes the Helm at kidSTREAM You know how it goes—sometimes you need fresh leadership to steer the ship. That's exactly what's happening over at kidSTREAM Children's Museum. They've appointed Carina Reeves as their President and CEO after a nationwide hunt. This ain't just another CEO shuffle; it marks a pivotal moment as kidSTREAM inches closer to its...